Preclinical Drug Discovery: v. 1: High Throughput Screening and Compound Progression Strategies.pdf
Drug discovery and the development requires the active collaboration of researchers from many scientific disciplines and sub-disciplines and the RSC has created a great opportunity to provide the necessary range of publications to facilitate this. Professor Robin Ganellin, University College London, UK
Dr Sheraz Gul is currently Vice President and Head of Biology at European ScreeningPort, Hamburg, Germany. He is responsible for the management of assay development and Medium and High Throughput Screening activities for academic and commercial partners across Europe. He has twelve years research experience in both academia (University of London) and industry (GlaxoSmithKline Pharmaceuticals). This has ranged from the detailed study of catalysis by biological catalysts (enzymes and catalytic antibodies) to the design and development of assays for High Throughput Screening. Whilst working at GSK he developed numerous biochemical and cellular assays for High Throughput Screening and evaluated compounds up to Candidate Selection. He is co-author of numerous papers, book chapters, and the Enzyme Assays: Essential Data Handbook. In addition, he is on the editorial board of the European Pharmaceutical Review for which he writes regular articles in the lab automation section.
Volume 1: Biochemical Methods in High Throughput Screening: Absorbance; Fluorescence intensity; Fluorescence polarisation; FRET, TR-FRET/HTRF; AlphaScreen; Fluorescence lifetime; Scintillation Proximity Assay; Chip based assays; Label free assays; Calorimetry; ELISA; Volume 2: Cell Based Methods in High Throughput Screening: Fluorescence intensity; FRET, TR-FRET/HTRF; AlphaScreen; Reporter gene assays; Luminescence & Bioluminescence; Scintillation Proximity Assay; Calcium mobilization (FLIPR); cAMP assays; Electrophysiology; Cellular imaging & fluorescent microscopy; Label free assays; Volume 3: Pre-Clinical Drug Discovery, High Throughput Screening and Compound Progression Strategies: The Drug Discovery process; Target classes and validation; Assays in Drug Discovery: biochemical vs cellular; Enzyme kinetics; Receptor kinetics in drug screening programmes; Biological reagents for High Throughput Screening; Automation vs manual operation of screening tasks; Analysis of High Throughput Screening data; Compound Mechanism of Action studies; Counter, Selectivity, Viability and Liability assays; Screening for undesirable compounds; Toxicology profiling; Compound characterization: physico-chemical properties; Index
This book is one of a three-volume set that provides theoretical, practical and troubleshooting guidelines on all aspects of the pre-clinical Drug Discovery process. There is particular focus on the design, development and role of screening assays in Drug Discovery, including new developments and future trends, the main assay types utilized in screening campaigns, and the methods utilized in enabling the progression of "Hits" to "Leads" and "Candidates" The books will also fill current gaps in the literature such as primary, stem cell and other novel assay methods. Other relatively new research areas included are siRNA, high content screening, protein-protein interactions, pathway assays, non micro-titre plate based assays, label free assays, IT tools, approaches to identify biopharmaceuticals, emerging models and future trends in Drug Discovery.